Dronedarone Hydrochloride Patent Expiration
Dronedarone Hydrochloride is Used for the management and treatment of atrial fibrillation in patients with risk factors such as coronary heart disease. It was first introduced by Sanofi Aventis Us Llc
Dronedarone Hydrochloride Patents
Given below is the list of patents protecting Dronedarone Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Multaq | US5223510 | Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them |
Jul 26, 2016
(Expired) | Sanofi Aventis Us |
| Multaq | US7323493 | Solid pharmaceutical composition containing benzofuran derivatives |
Jun 19, 2018
(Expired) | Sanofi Aventis Us |
| Multaq | US8318800 | Solid pharmaceutical compositions containing benzofuran derivatives |
Jun 19, 2018
(Expired) | Sanofi Aventis Us |
| Multaq | US8410167 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality | Apr 16, 2029 | Sanofi Aventis Us |
| Multaq | US8602215 | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation | Jun 30, 2031 | Sanofi Aventis Us |
| Multaq | US9107900 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality | Apr 16, 2029 | Sanofi Aventis Us |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Dronedarone Hydrochloride Generics
Only one generic application has been filed for Dronedarone Hydrochloride.
Given below is the list of companies who have filed for Dronedarone Hydrochloride generic.
1. LUPIN
Lupin Inc has filed for 1 generic for Dronedarone Hydrochloride. Given below are the details of the strengths of this generic introduced by Lupin.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 400MG BASE | tablet | Prescription | ORAL | AB | Jan 31, 2024 |